



## Pituitary Tumors: New Insights into Molecular Features, Diagnosis and Therapeutic Targeting

Guest Editor:

**Prof. Dr. Monica Fedele**

CNR—Institute of Experimental  
Endocrinology and Oncology,  
80131 Naples, Italy

Deadline for manuscript  
submissions:

**closed (30 September 2019)**

### Message from the Guest Editor

Dear Colleagues,

Recent progress in understanding the molecular features of pituitary adenomas, one of the most frequent intracranial tumors and neuroendocrine neoplasms affecting 1 in 1000 in the general population, allowed us to improve their classification, with an impact on the diagnosis and the prediction of targeted treatments. Pituitary tumorigenesis is driven by diverse mechanisms, including gene amplification, mutation, overexpression, down-regulation and epigenetic silencing, microRNA misexpression, cell cycle dysregulation, endocrine dysfunction, and others.

A deep knowledge of each of these mechanisms, mainly achieved thanks to the use of animal models, is leading to the development of effective therapeutic strategies, even for the most aggressive subtypes, characterized by invasiveness, recurrence, and resistance to conventional treatment.

In this Special Issue, we will publish reviews and original research that provide new insights into signaling pathways and biomarkers driving pituitary tumorigenesis, diagnosis, and therapeutic perspectives. Articles about aggressive pituitary adenomas will be particularly welcomed.

Prof. Dr. Monica Fedele

*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)